secwatch / observer

8-K filed May 4, 2026, 7:59 PM ET ticker ONCY CIK 0001129928

other material confidence high sentiment positive materiality 0.85

Oncolytics reports 19.5-month median DOR in 2L RAS-mutant MSS mCRC; triples ORR vs SOC

ONCOLYTICS BIOTECH INC

Pelareorep-based combo shows median duration of response 19.5 months in 2L KRAS-mutant MSS mCRC, vs historical 4–6 months.
Objective response rate 33% with pelareorep+FOLFIRI+bevacizumab, tripling the 6-11% standard of care.
Company actively engaging FDA to support potential accelerated approval pathway in this indication.
REO 022 study continues enrollment in randomized Phase 2 for 2L RAS-mutant MSS mCRC.
Data highlight durable benefit in a difficult-to-treat colorectal cancer population with few options.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001129928-26-000028
form_type: 8-K
ticker: ONCY
cik: 0001129928
company_name: ONCOLYTICS BIOTECH INC
filed_at: 2026-05-04T23:59:59+00:00
discovered_at: 2026-05-14T18:02:31.988849+00:00
generated_at: 2026-05-14T23:49:47.105923+00:00
sec_items: ["8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001129928-26-000028
json_url: https://secwatch.observer/filing/0001129928-26-000028.json
markdown_url: https://secwatch.observer/filing/0001129928-26-000028.md
text_url: https://secwatch.observer/filing/0001129928-26-000028.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000028/0001129928-26-000028-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000028/oncy-20260504.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

QMCO

Quantum raises $100M equity, converts all convertible notes to equity; Q4 revenue above guidance

QUANTUM CORP /DE/ June 2, 2026, 10:41 AM ET other_material Items 1.01, 2.02, 2.03, 3.02, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CELC

Gedatolisib doubles PFS vs alpelisib in PIK3CA mutant HR+/HER2- ABC Phase 3 trial

Celcuity Inc. June 2, 2026, 8:10 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CSR

Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City

CENTERSPACE June 1, 2026, 4:30 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

DGAC

Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE

DISCIPLINED GROWTH ACQUISITION Corp June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

FULC

Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review

Fulcrum Therapeutics, Inc. June 1, 2026, 4:05 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

USAR

USA Rare Earth selects South Carolina for $1.2B magnet facility; 490 jobs, 6,400 tpa capacity

USA Rare Earth, Inc. June 2, 2026, 9:14 AM ET other_material Items 1.01, 2.03, 7.01, 9.01

same SEC item: 9.01 same event type: other_material similar materiality

Filing page SEC filing

IVF

INVO Fertility restates 2025 Q1-Q3 financials; non-reliance due to accounting errors

INVO Fertility, Inc. June 2, 2026, 8:30 AM ET other_material Items 4.02, 9.01

same SEC item: 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001129928-26-000028

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.